Report Detail

Pharma & Healthcare Mylan NV (MYL) - Financial and Strategic SWOT Analysis Review

  • RnM1866132
  • |
  • 20 May, 2019
  • |
  • United Kingdom
  • |
  • 70 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Mylan NV (MYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mylan NV (Mylan) is a pharmaceutical company that develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceuticals in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer. It also offers anti-retrovirals, anaphylaxis products, and active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV Key Recent Developments

May 10,2019 Mylan Expands Oncology Portfolio with Launch of Generic Tarceva Tablets
Mar 07,2019 SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation
Feb 26,2019 Mylan reports fourth quarter and full year 2018 results and provides 2019 guidance
Jan 31,2019 Mylan Snags FDA Approval for Its Generic Version of GSK’s Advair

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents

      List of Tables

        List of Figures

          Section 1 - About the Company

            Mylan NV - Key Facts

              Mylan NV - Key Employees

                Mylan NV - Key Employee Biographies

                  Mylan NV - Major Products and Services

                    Mylan NV - History

                      Mylan NV - Company Statement

                        Mylan NV - Locations And Subsidiaries

                          Head Office

                            Other Locations & Subsidiaries

                              Section 2 – Company Analysis

                                Company Overview

                                  Mylan NV - Business Description

                                    Product Category: Net Sales

                                      Performance

                                        Product Category: Other Revenue

                                          Performance

                                            Product Category: Europe

                                              Overview

                                                Performance

                                                  Product Category: North America

                                                    Overview

                                                      Performance

                                                        Key Stats

                                                          Product Category: Rest of World

                                                            Overview

                                                              Performance

                                                                Key Stats

                                                                  R&D Overview

                                                                    Mylan NV - SWOT Analysis

                                                                      SWOT Analysis - Overview

                                                                        Mylan NV - Strengths

                                                                          Mylan NV - Weaknesses

                                                                            Mylan NV - Opportunities

                                                                              Mylan NV - Threats

                                                                                Mylan NV - Key Competitors

                                                                                  Section 3 – Company Financial Ratios

                                                                                    Financial Ratios - Capital Market Ratios

                                                                                      Financial Ratios - Annual Ratios

                                                                                        Performance Chart

                                                                                          Financial Performance

                                                                                            Financial Ratios - Interim Ratios

                                                                                              Financial Ratios - Ratio Charts

                                                                                                Section 4 – Company’s Lifesciences Financial Deals and Alliances

                                                                                                  Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

                                                                                                    Mylan NV, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

                                                                                                      Mylan NV, Recent Deals Summary

                                                                                                        Section 5 – Company’s Recent Developments

                                                                                                          May 10, 2019: Mylan Expands Oncology Portfolio with Launch of Generic Tarceva Tablets

                                                                                                            Mar 07, 2019: SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable Foundation

                                                                                                              Feb 26, 2019: Mylan reports fourth quarter and full year 2018 results and provides 2019 guidance

                                                                                                                Jan 31, 2019: Mylan Snags FDA Approval for Its Generic Version of GSK’s Advair

                                                                                                                  Dec 06, 2018: Mylan recalls all lots of blood pressure drugs containing valsartan

                                                                                                                    Dec 04, 2018: Mylan recalls 1.2 million bottles of 'made in India' BP drug from US

                                                                                                                      Nov 27, 2018: FDA Issues Warning Letter to Mylan Pharmaceuticals

                                                                                                                        Nov 20, 2018: Mylan statement in response to FDA warning letter relating to Morgantown Plant

                                                                                                                          Nov 20, 2018: Mylan initiates voluntary nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the detection of trace amounts of NDEA (N-Nitrosodiethylamine) Impurity Fou

                                                                                                                            Section 6 – Appendix

                                                                                                                              Methodology

                                                                                                                                Ratio Definitions

                                                                                                                                  About GlobalData

                                                                                                                                    Contact Us

                                                                                                                                      Disclaimer


                                                                                                                                      REPORT YOU MIGHT BE INTERESTED

                                                                                                                                      Purchase this Report

                                                                                                                                      $500.00
                                                                                                                                      $1,000.00
                                                                                                                                      $1,500.00
                                                                                                                                      400.50
                                                                                                                                      801.00
                                                                                                                                      1,201.50
                                                                                                                                      467.00
                                                                                                                                      934.00
                                                                                                                                      1,401.00
                                                                                                                                      78,745.00
                                                                                                                                      157,490.00
                                                                                                                                      236,235.00
                                                                                                                                      41,695.00
                                                                                                                                      83,390.00
                                                                                                                                      125,085.00
                                                                                                                                      Credit card Logo

                                                                                                                                      Related Reports


                                                                                                                                      Reason to Buy

                                                                                                                                      Request for Sample of this report